Loading stock data…
Revvity (RVTY)
$111.21-1.81 (-1.60%)
After Hours$111.21+0.00 (+0.00%)· Last close Jun 29
Revvity, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revvity, Inc. in the Healthcare sector is trading at $111.21 with a market capitalization of $11.3B. Wall Street consensus targets $113.73 (15 analysts), implying a +2.3% move over the next 12 months. The stock is currently near its 52-week high of $118.30, remaining 15.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $711.12M↓ | $772.06M↑ | $698.95M↓ | $720.28M↑ | $664.76M |
| Gross Profit | $387.65M↓ | $421.66M↑ | $374.60M↓ | $392.56M↑ | $375.55M |
| Operating Income | $75.89M↓ | $111.75M↑ | $81.90M↓ | $89.06M↑ | $72.23M |
| Net Income | $40.72M↓ | $98.36M↑ | $46.65M↓ | $53.95M↑ | $42.24M |
Peer Comparison
JNJUNHPFE
Fundamentals
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.25%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.34%
Volume
Today's trading volume
1.69M
Recent News
3 S&P 500 Stocks We’re Skeptical Of
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Revvity Launches Signals AI to Advance Scientific R&D Workflows
RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.
Is Revvity Stock Underperforming the Nasdaq?
Revvity has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.
2 Profitable Stocks with Impressive Fundamentals and 1 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Revvity (RVTY) Valuation Check After China Immunodiagnostics Exit Plan And Solid First Quarter Results
Revvity (RVTY) is back in focus after announcing plans to divest its China immunodiagnostics business, a unit facing policy and cash flow headwinds, alongside reporting solid first quarter revenue and margin figures. See our latest analysis for Revvity. The stock has given up some ground in the past week, with a 1-day share price decline of 3.94% and a 7-day share price return of 2.14% lower. However, the 90-day share price return is up 8.94% and the 1-year total shareholder return is 6.21%,...